{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T13:44:01Z","timestamp":1777383841429,"version":"3.51.4"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["SAF2010-16024"],"award-info":[{"award-number":["SAF2010-16024"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["SAF2013-44416-R"],"award-info":[{"award-number":["SAF2013-44416-R"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["FIS-FEDER PI07-1168"],"award-info":[{"award-number":["FIS-FEDER PI07-1168"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Eye Research"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.exer.2022.109036","type":"journal-article","created":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T04:48:27Z","timestamp":1648702107000},"page":"109036","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Therapeutic potential of topical administration of siRNAs against HIF-1\u03b1 for corneal neovascularization"],"prefix":"10.1016","volume":"219","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7495-3088","authenticated-orcid":false,"given":"Assumpta","family":"Peral","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jes\u00fas","family":"Mateo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen O.","family":"Dom\u00ednguez-God\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gonzalo","family":"Carracedo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose Antonio","family":"G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Almudena","family":"Crooke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jes\u00fas","family":"Pintor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.exer.2022.109036_bib1","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1556\/APhysiol.96.2009.1.2","article-title":"HIF-1: a key mediator in hypoxia","volume":"96","author":"Adams","year":"2009","journal-title":"Acta Physiol. Hung."},{"key":"10.1016\/j.exer.2022.109036_bib2","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3341\/kjo.2014.28.2.177","article-title":"Ranibizumab injection for corneal neovascularization refractory to bevacizumab treatment","volume":"28","author":"Ahn","year":"2014","journal-title":"Kor. J. Ophthalmol."},{"key":"10.1016\/j.exer.2022.109036_bib3","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.sjopt.2017.02.008","article-title":"Topical versus subconjunctival anti-vascular endothelial growth factor therapy (Bevacizumab, Ranibizumab and Aflibercept) for treatment of corneal neovascularization","volume":"31","author":"Al-Debasi","year":"2017","journal-title":"Saudi J Ophthalmol"},{"key":"10.1016\/j.exer.2022.109036_bib4","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1373\/49.1.32","article-title":"Angiogenesis assays: a critical overview","volume":"49","author":"Auerbach","year":"2003","journal-title":"Clin. Chem."},{"key":"10.1016\/j.exer.2022.109036_bib5","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/0163-7258(94)90027-2","article-title":"Angiogenesis inhibition: a review","volume":"63","author":"Auerbach","year":"1994","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.exer.2022.109036_bib6","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/j.ophtha.2010.01.039","article-title":"Corneal neovascularization as a risk factor for graft failure and rejection after keratoplasty: an evidence-based meta-analysis","volume":"117","author":"Bachmann","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.exer.2022.109036_bib7","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1002\/ijc.29519","article-title":"HIF-1 at the crossroads of hypoxia, inflammation, and cancer","volume":"138","author":"Balamurugan","year":"2016","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.exer.2022.109036_bib8","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.omtn.2020.07.012","article-title":"Introducing an in vitro liver stability Assay capable of predicting the in vivo pharmacodynamic efficacy of siRNAs for IVIVC","volume":"21","author":"Basiri","year":"2020","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.exer.2022.109036_bib9","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1002\/med.21477","article-title":"Hypoxia-inducible factor-1 (HIF-1) inhibitors from the last decade (2007 to 2016): a \"structure-activity relationship\" perspective","volume":"38","author":"Bhattarai","year":"2018","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.exer.2022.109036_bib10","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/sj.gt.3302653","article-title":"Potential applications for RNAi to probe pathogenesis and develop new treatments for ocular disorders","volume":"13","author":"Campochiaro","year":"2006","journal-title":"Gene Ther."},{"key":"10.1016\/j.exer.2022.109036_bib11","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.ajo.2015.07.031","article-title":"Terrien marginal degeneration: clinical characteristics and outcomes","volume":"160","author":"Chan","year":"2015","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.exer.2022.109036_bib12","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/00055735-200108000-00002","article-title":"Corneal neovascularization","volume":"12","author":"Chang","year":"2001","journal-title":"Curr. Opin. Ophthalmol."},{"key":"10.1016\/j.exer.2022.109036_bib13","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.2165\/00003495-200868080-00002","article-title":"Neovascular age-related macular degeneration: potential therapies","volume":"68","author":"Chappelow","year":"2008","journal-title":"Drugs"},{"key":"10.1016\/j.exer.2022.109036_bib14","first-page":"864","article-title":"Inhibition of VEGF expression and corneal neovascularization by shRNA targeting HIF-1alpha in a mouse model of closed eye contact lens wear","volume":"18","author":"Chen","year":"2012","journal-title":"Mol. Vis."},{"key":"10.1016\/j.exer.2022.109036_bib15","series-title":"Adler's Physiology of the Eye","first-page":"47","article-title":"Cornea and sclerotica","author":"Edelhauser","year":"2004"},{"key":"10.1016\/j.exer.2022.109036_bib16","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/00003226-198706040-00004","article-title":"Corneal neovascularization. Pathogenesis and inhibition","volume":"6","author":"Epstein","year":"1987","journal-title":"Cornea"},{"key":"10.1016\/j.exer.2022.109036_bib17","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1097\/ICO.0b013e3182775f8d","article-title":"Topical ranibizumab as a treatment of corneal neovascularization","volume":"32","author":"Ferrari","year":"2013","journal-title":"Cornea"},{"key":"10.1016\/j.exer.2022.109036_bib18","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/nm0195-27","article-title":"Angiogenesis in cancer, vascular, rheumatoid and other disease","volume":"1","author":"Folkman","year":"1995","journal-title":"Nat. Med."},{"key":"10.1016\/j.exer.2022.109036_bib19","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20180552","article-title":"Inhibited corneal neovascularization in rabbits following corneal alkali burn by double-target interference for VEGF and HIF-1alpha","volume":"39","author":"Fu","year":"2019","journal-title":"Biosci. Rep."},{"key":"10.1016\/j.exer.2022.109036_bib20","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0141-7037(85)80002-1","article-title":"Limbal changes associated with hydrogelcontact lens wear","volume":"8","author":"Guillon","year":"1985","journal-title":"J. Br. Contact Lens Assoc."},{"key":"10.1016\/j.exer.2022.109036_bib21","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1097\/ICO.0b013e318201405a","article-title":"Treatments for corneal neovascularization: a review","volume":"30","author":"Gupta","year":"2011","journal-title":"Cornea"},{"key":"10.1016\/j.exer.2022.109036_bib22","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1002\/mabi.201600051","article-title":"Reducible polyethylenimine nanoparticles for efficient siRNA delivery in corneal neovascularization therapy","volume":"16","author":"Han","year":"2016","journal-title":"Macromol. Biosci."},{"key":"10.1016\/j.exer.2022.109036_bib23","first-page":"799","article-title":"Genome-wide gene expression profiles of clear cell renal cell carcinoma: identification of molecular targets for treatment of renal cell carcinoma","volume":"29","author":"Hirota","year":"2006","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.exer.2022.109036_bib24","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/j.1444-0938.1986.tb06800.x","article-title":"The vascular response to long-term extended contact lens wear","volume":"69","author":"Holden","year":"1986","journal-title":"Clin. Exp. Optom."},{"key":"10.1016\/j.exer.2022.109036_bib25","doi-asserted-by":"crossref","first-page":"6080","DOI":"10.1523\/JNEUROSCI.5493-09.2010","article-title":"Pharmacological and genetic accumulation of hypoxia-inducible factor-1alpha enhances excitatory synaptic transmission in hippocampal neurons through the production of vascular endothelial growth factor","volume":"30","author":"Huang","year":"2010","journal-title":"J. Neurosci."},{"key":"10.1016\/j.exer.2022.109036_bib26","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.jconrel.2013.10.008","article-title":"Sustained delivery of a HIF-1 antagonist for ocular neovascularization","volume":"172","author":"Iwase","year":"2013","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.exer.2022.109036_bib27","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1002\/cpt.1846","article-title":"Does in vitro potency predict clinically efficacious concentrations?","volume":"108","author":"Jansson-L\u00f6fmark","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.exer.2022.109036_bib28","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ajo.2010.02.006","article-title":"RNAi-based treatment for neovascular age-related macular degeneration by Sirna-027","volume":"150","author":"Kaiser","year":"2010","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.exer.2022.109036_bib29","doi-asserted-by":"crossref","first-page":"7637","DOI":"10.1167\/iovs.14-15430","article-title":"Transgenic mouse models of corneal neovascularization: new perspectives for angiogenesis research","volume":"55","author":"Kather","year":"2014","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.exer.2022.109036_bib30","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1016\/S0002-9440(10)63267-1","article-title":"Inhibition of ocular angiogenesis by siRNA targeting vascular endothelial growth factor pathway genes: therapeutic strategy for herpetic stromal keratitis","volume":"165","author":"Kim","year":"2004","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.exer.2022.109036_bib31","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1177\/1947601911423654","article-title":"Hypoxia-induced angiogenesis: good and evil","volume":"2","author":"Krock","year":"2011","journal-title":"Genes Cancer"},{"key":"10.1016\/j.exer.2022.109036_bib32","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0039-6257(98)00035-6","article-title":"Ocular neovascularization: an epidemiologic review","volume":"43","author":"Lee","year":"1998","journal-title":"Surv. Ophthalmol."},{"key":"10.1016\/j.exer.2022.109036_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00003226-200101000-00001","article-title":"Herpes simplex virus epidemiology and ocular importance","volume":"20","author":"Liesegang","year":"2001","journal-title":"Cornea"},{"key":"10.1016\/j.exer.2022.109036_bib34","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1097\/BCR.0b013e31822b0f29","article-title":"Management of ocular conditions in the burn unit: thermal and chemical burns and Stevens-Johnson syndrome\/toxic epidermal necrolysis","volume":"32","author":"Lin","year":"2011","journal-title":"J. Burn Care Res."},{"key":"10.1016\/j.exer.2022.109036_bib35","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1097\/00006982-200501000-00020","article-title":"Intravitreal injection of VEGF siRNA","volume":"25","author":"Maguire","year":"2005","journal-title":"Retina"},{"key":"10.1016\/j.exer.2022.109036_bib36","series-title":"Nongonococcal Urethritis and Related Infection","first-page":"67","article-title":"Biological characteristics of chlamydiae","author":"Manire","year":"1997"},{"key":"10.1016\/j.exer.2022.109036_bib37","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/mt.2013.216","article-title":"In vitro and in vivo efficacy of SYL040012, a novel siRNA compound for treatment of glaucoma","volume":"22","author":"Martinez","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.exer.2022.109036_bib38","first-page":"49","article-title":"Dise\u00f1o de un modelo experimental de causticaci\u00f3n corneal con compromiso l\u00edmbico (grado III, Thof)","volume":"72","author":"Mendicute","year":"1997","journal-title":"Arch. Sociedad espa\u00f1ola de Oftalmolog\u00eda"},{"key":"10.1016\/j.exer.2022.109036_bib39","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1038\/eye.2012.106","article-title":"Phase 1 dose-escalation study of a siRNA targeting the RTP801 gene in age-related macular degeneration patients","volume":"26","author":"Nguyen","year":"2012","journal-title":"Eye"},{"key":"10.1016\/j.exer.2022.109036_bib40","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1016\/j.ophtha.2012.03.043","article-title":"Evaluation of the siRNA PF-04523655 versus ranibizumab for the treatment of neovascular age-related macular degeneration (MONET Study)","volume":"119","author":"Nguyen","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.exer.2022.109036_bib41","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1109\/TSMC.1979.4310076","article-title":"A threshold selection method from gray-level histograms","volume":"9","author":"Otsu","year":"1979","journal-title":"IEEE Transactions on Systems, Man, and Cybernetics"},{"key":"10.1016\/j.exer.2022.109036_bib42","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1006\/exer.1998.0504","article-title":"On the relationship between soft contact lens oxygen transmissibility and induced limbal hyperaemia","volume":"67","author":"Papas","year":"1998","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.exer.2022.109036_bib43","doi-asserted-by":"crossref","first-page":"S72","DOI":"10.1097\/00140068-200301001-00020","article-title":"The role of hypoxia in the limbal vascular response to soft contact lens wear","volume":"29","author":"Papas","year":"2003","journal-title":"Eye Contact Lens"},{"key":"10.1016\/j.exer.2022.109036_bib44","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/nm0603-677","article-title":"Regulation of angiogenesis by hypoxia: role of the HIF system","volume":"9","author":"Pugh","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.exer.2022.109036_bib45","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.prostaglandins.2007.05.001","article-title":"Inhibition of VEGF expression and corneal neovascularization by siRNA targeting cytochrome P450 4B1","volume":"84","author":"Seta","year":"2007","journal-title":"Prostag. Other Lipid Mediat."},{"key":"10.1016\/j.exer.2022.109036_bib46","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/ICO.0b013e31802b4201","article-title":"Unique homologous siRNA blocks hypoxia-induced VEGF upregulation in human corneal cells and inhibits and regresses murine corneal neovascularization","volume":"26","author":"Singh","year":"2007","journal-title":"Cornea"},{"key":"10.1016\/j.exer.2022.109036_bib47","doi-asserted-by":"crossref","first-page":"108329","DOI":"10.1016\/j.exer.2020.108329","article-title":"Role of small interfering RNA (siRNA) in targeting ocular neovascularization: a review","volume":"202","author":"Supe","year":"2021","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.exer.2022.109036_bib48","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1001\/jama.1986.03370240048035","article-title":"Blindness in Saudi arabia","volume":"255","author":"Tabbara","year":"1986","journal-title":"JAMA"},{"key":"10.1016\/j.exer.2022.109036_bib49","series-title":"Infections of the Eye","first-page":"673","article-title":"Ocular onchocerciasis","author":"Taylor","year":"1996"},{"key":"10.1016\/j.exer.2022.109036_bib50","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1097\/00006982-200408000-00039","article-title":"Intravitreal injection of vascular endothelial growth factor small interfering RNA inhibits growth and leakage in a nonhuman primate, laser-induced model of choroidal neovascularization","volume":"24","author":"Tolentino","year":"2004","journal-title":"Retina"},{"key":"10.1016\/j.exer.2022.109036_bib51","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3109\/02713681003597230","article-title":"A siRNA targeting vascular endothelial growth factor-A inhibiting experimental corneal neovascularization","volume":"35","author":"Zuo","year":"2010","journal-title":"Curr. Eye Res."}],"container-title":["Experimental Eye Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014483522001178?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014483522001178?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T05:32:43Z","timestamp":1762147963000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014483522001178"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":51,"alternative-id":["S0014483522001178"],"URL":"https:\/\/doi.org\/10.1016\/j.exer.2022.109036","relation":{},"ISSN":["0014-4835"],"issn-type":[{"value":"0014-4835","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic potential of topical administration of siRNAs against HIF-1\u03b1 for corneal neovascularization","name":"articletitle","label":"Article Title"},{"value":"Experimental Eye Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exer.2022.109036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"109036"}}